BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of Common Stock for resale by selling securityholders under a prospectus supplement dated March 26, 2026. The supplement amends the Form S-1 prospectus dated September 10, 2025 and attaches a Form 8-K reporting a board appointment.
The prospectus supplement states the resale is by selling securityholders (not an issuer primary sale); the company will not receive proceeds from these resales. The attached Form 8-K discloses the appointment of Peter Lebowitz, M.D., Ph.D. to the Board and a one-time option grant of 63,350 shares at an exercise price of $8.72 per share.
BridgeBio Oncology Therapeutics, Inc. reported that its board expanded to nine directors and appointed Peter Lebowitz, M.D., Ph.D. as a Class I director effective March 24, 2026. His term runs until the 2026 annual stockholders meeting and he will serve on the nominating and governance and compensation committees.
The board determined Dr. Lebowitz is independent under Nasdaq and applicable regulations and disclosed no related-party arrangements or transactions requiring Regulation S-K Item 404(a) disclosure. As a non-employee director, he will receive standard board compensation, including a one-time stock option for 63,350 common shares at an exercise price of $8.72 per share, matching the Nasdaq Global Market closing price on March 24, 2026. He also entered into the company’s standard indemnification agreement covering certain expenses and liabilities arising from his board service.
BridgeBio Oncology Therapeutics, Inc. reported that Chief Financial Officer Uneek Mehra received new equity awards. On March 10, 2026, he was granted stock options covering 105,000 shares of common stock at an exercise price of $10.19 per share, expiring on March 9, 2036.
The option vests in substantially equal monthly installments, with 1/48 of the shares vesting each month from January 1, 2026, contingent on continued service. He also received 23,330 restricted stock units, each representing one share of common stock, vesting in 16 equal quarterly installments over four years from January 1, 2026, and settling in shares upon vesting.
BridgeBio Oncology Therapeutics, Inc. Chief Scientific Officer Pedro Beltran received new equity awards as part of his compensation. He was granted an option for 210,000 shares of common stock at an exercise price of 10.19 per share, vesting in substantially equal monthly installments from January 1, 2026.
He also received 46,670 restricted stock units, each representing one share of common stock. These RSUs vest in 16 equal quarterly installments over four years from January 1, 2026, and are settled in shares upon vesting, subject to his continued service.
BridgeBio Oncology Therapeutics, Inc. reported that Chief Medical & Development Officer Ben Yong received new equity awards on March 10, 2026. He was granted a stock option for 210,000 shares of Common Stock at an exercise price of $10.19 per share, expiring in 2036.
He also received 46,670 restricted stock units (RSUs), each representing one share of Common Stock. The RSUs vest in 16 equal quarterly installments over four years from January 1, 2026, and the option vests in 48 substantially equal monthly installments from the same date, in each case contingent on continued service.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of Common Stock for resale by selling securityholders under Prospectus Supplement No. 3. This supplement, dated March 6, 2026, attaches the company’s Form 10-K for the fiscal year ended December 31, 2025 and updates the base prospectus dated September 10, 2025.
Shares outstanding were 80,032,823 as of March 2, 2026, reported in the Form 10-K; the supplement states the March 5, 2026 closing Nasdaq price of $9.89 per share.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical‑stage biotech formed via an August 2025 business combination between Helix Acquisition Corp. II and Legacy BBOT. The company focuses on cancers driven by KRAS and PI3Kα using three oral small‑molecule programs.
BBO‑8520, a dual ON/OFF KRAS G12C inhibitor, showed a 65% objective response rate (11/17 NSCLC patients) and 68% 6‑month progression‑free survival as of November 15, 2025, with no dose‑limiting toxicities or grade 3+ liver toxicity reported. Combination data with pembrolizumab showed tumor reductions in all eight evaluable patients.
BBO‑11818, a dual ON/OFF pan‑KRAS inhibitor, has early Phase 1 data including a confirmed partial response with 56% tumor reduction in pancreatic cancer. BBO‑10203, a PI3Kα “breaker,” showed tumor regressions in preclinical models and early clinical activity without hyperglycemia, supporting combination strategies across lung, colorectal, breast and pancreatic cancers. BBOT reports no approved products or revenue and highlights extensive development, regulatory, financing and market risks.
BridgeBio Oncology Therapeutics reported fourth quarter and full year 2025 results alongside major progress in its RAS-pathway cancer pipeline. The company ended 2025 with cash, cash equivalents and marketable securities of $425.5 million, which it expects will fund operations into 2028.
For 2025, research and development expenses rose to $121.2 million from $73.1 million, and general and administrative costs increased to $24.6 million from $7.8 million, reflecting expanded clinical activity and standalone operations after its SPAC transaction. Net loss widened to $134.0 million from $74.3 million.
Clinically, BBO-8520 showed a 65% objective response rate and 68% 6‑month progression-free survival in KRASG12C lung cancer, BBO-11818 delivered a confirmed partial response with a 56% tumor reduction in pancreatic cancer, and BBO-10203 achieved full target engagement with no observed hyperglycemia. Updated readouts across all three programs are expected in the second half of 2026.
BridgeBio Oncology Therapeutics, Inc. reported that it issued a press release sharing new clinical data for three innovative and differentiated RAS and PI3Kα pipeline programs.
The press release, dated January 7, 2026 and titled “BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs,” is attached as an exhibit to this current report, with the full scientific and clinical details contained in that separate document.
BridgeBio Oncology Therapeutics, Inc. reported an update to its Chief Executive Officer and director’s stock option grant. On December 10, 2025, the company rescinded 1,114,400 stock options from an option grant originally dated October 2, 2025, as an exempt disposition to the issuer under Rule 16b-3.
After this change, 500,000 stock options from the original grant remain outstanding, each with an exercise price of $12.44 and an expiration date of October 1, 2035. The options vest in 48 substantially equal monthly installments beginning on the monthly anniversary of October 2, 2025, as long as the reporting person continues to provide service to the company on each vesting date.